Eduovisual
Endocrine
Diabetes insipidus: central vs nephrogenic
— CDI: hypothalamic/posterior pituitary failure to secrete ADH (vasopressin)
— NDI: collecting duct V2 receptor or aquaporin-2 dysfunction despite adequate ADH
— Outpatient: chronic polyuria + polydipsia, nocturia, unexplained hypernatremia on routine labs
— Inpatient: post-neurosurgery/pituitary surgery patient with sudden urine output >300 mL/hr and rising Na⁺
— TBI, subarachnoid hemorrhage, anoxic brain injury patients with brisk dilute urine
— Patient on lithium for years presenting with polyuria → NDI until proven otherwise
— Hypercalcemia or chronic hypokalemia with polyuria
Step 3 management: In any postoperative pituitary or transsphenoidal surgery patient, monitor strict I/Os and serum Na⁺ q6h for the first 48–72 hours — the classic triphasic response (DI → SIADH → permanent DI) catches unwary clinicians. If urine output >250 mL/hr for 2 consecutive hours with rising Na⁺ and Uosm <300, begin desmopressin workup immediately rather than waiting for formal water deprivation testing.
Board pearl: Patients with intact thirst and free water access often maintain near-normal Na⁺ — hypernatremia in DI implies impaired thirst, restricted access, or acute onset.
— Abrupt onset, exact date the patient can name → classic for central DI (often post-trauma, post-surgical, idiopathic autoimmune)
— Gradual, lifelong, family history → hereditary NDI (X-linked AVPR2 mutation in boys; autosomal AQP2)
— Years of lithium therapy, slow onset → acquired NDI
— Head trauma, neurosurgery, pituitary tumor, craniopharyngioma, Sheehan syndrome, lymphocytic hypophysitis, granulomatous disease (sarcoid, Langerhans cell histiocytosis, TB), metastases (breast, lung)
— Medications: lithium, demeclocycline, foscarnet, amphotericin B, cidofovir, tolvaptan
— Electrolyte history: chronic hypercalcemia, hypokalemia
— Pregnancy (gestational DI from placental vasopressinase, third trimester)
— Psychiatric history (primary polydipsia mimic)
Key distinction: Primary (psychogenic) polydipsia patients drink first, then urinate; DI patients urinate first and drink to compensate. Asking "If you couldn't drink for several hours, would you feel desperately thirsty?" — a DI patient says yes emphatically; a primary polydipsia patient often says no.
Board pearl: A craving specifically for ice water is highly suggestive of central DI and rare in primary polydipsia or NDI.
Step 3 management: In ambulatory polyuria workup, before ordering expensive testing, always check finger-stick glucose, basic metabolic panel, serum and urine osmolality, and urine specific gravity — this single panel often differentiates osmotic diuresis (glucose, urea) from true water diuresis and frames the rest of the workup.
— With intact thirst and water access: euvolemic, normal vitals, normal mucous membranes
— Without access (NPO, intubated, elderly nursing home, infant, postictal): hypovolemia — dry mucosa, tachycardia, orthostasis, hypotension, decreased skin turgor, sunken fontanelle in infants
— Lethargy, irritability, hyperreflexia, muscle twitching, seizures, coma
— Focal deficits suggest underlying CNS lesion (mass, hemorrhage)
— Visual field testing (bitemporal hemianopsia) → pituitary/suprasellar mass causing CDI
— Café-au-lait spots, precocious puberty → McCune-Albright (rare)
— Skin: rash of Langerhans cell histiocytosis, sarcoid lesions, eczema/seborrhea in infants with LCH
— Goiter, exophthalmos, signs of other pituitary hormone deficits (short stature, hypogonadism, hypothyroidism, adrenal insufficiency)
— Lithium tremor, fine resting tremor, hyperreflexia
— Tachycardia + hypotension + hypernatremia = severe free water deficit, escalate fluids
— Normotensive with high-normal Na⁺ and high urine output = compensated DI, can manage outpatient
CCS pearl: On the CCS case, order vitals, daily weights, strict I/Os, and serum sodium q6h for any patient with suspected acute DI. These standing orders alone catch deterioration faster than waiting for symptoms.
Board pearl: A postoperative pituitary patient with normal blood pressure but urine output of 400 mL/hr and rising Na⁺ from 140 → 148 over 6 hours has acute central DI; do not wait for hypotension before acting.
Key distinction: Hypovolemia in DI is free water loss (hypernatremic dehydration) — replace with hypotonic fluids; contrast with GI losses where isotonic replacement is preferred.
— Serum electrolytes (Na⁺, K⁺, Ca²⁺, glucose, BUN/Cr)
— Serum osmolality (Posm)
— Urine osmolality (Uosm) and urine specific gravity
— 24-hour urine volume
— Urinalysis (rule out glucosuria)
— Polyuria >3 L/day with Uosm <300 mOsm/kg (often <100 in complete DI)
— Urine specific gravity <1.005
— Posm normal or high (>295) with Na⁺ normal or high (>142)
— Uosm/Posm ratio <1
— Glucose >180 mg/dL with glucosuria → osmotic diuresis from uncontrolled diabetes
— Recent mannitol, contrast, diuretics, relief of urinary obstruction → solute diuresis (urine has high solute, Uosm typically >300)
— Hypercalcemia or hypokalemia → can both cause acquired NDI; correct and reassess
— BUN elevation suggests dehydration severity
— Random Posm >295 + Uosm <300 → DI essentially confirmed; proceed directly to desmopressin challenge (skip water deprivation)
— Posm 280–295 + Uosm <300 + polyuria → formal water deprivation testing needed to distinguish DI from primary polydipsia
— Posm <280 + low Uosm → primary polydipsia likely
— Pituitary panel: TSH, free T4, AM cortisol, ACTH, prolactin, LH/FSH, IGF-1
— Calcium, glucose, lithium level if relevant
— Urine drug screen if unclear
Step 3 management: Before any water deprivation test, rule out adrenal insufficiency; cortisol deficiency suppresses free water excretion and can mask DI or cause dangerous hyponatremia during testing.
Board pearl: A spot urine specific gravity ≥1.020 essentially excludes untreated DI — if a patient claims severe polyuria but produces concentrated urine, suspect primary polydipsia or inaccurate history.
Key distinction: Solute diuresis = high urine solute output (Uosm × volume); water diuresis (DI) = high volume, low solute. A 24-hour urine sodium and urea can disambiguate.
— Withhold fluids under monitored conditions; measure hourly weight, vitals, Uosm, Posm, Na⁺
— Stop when: weight loss >3–5%, Posm >295, or Uosm plateaus (<30 mOsm/kg change over 2–3 hr)
— Then administer desmopressin (DDAVP) 2 µg IV/SC or 10 µg intranasal; measure Uosm at 1 and 2 hours
— Complete central DI: Uosm rises >50% (often doubles) after DDAVP
— Partial central DI: Uosm rises 15–50%
— Nephrogenic DI: Uosm rises <10–15% (no response)
— Primary polydipsia: Uosm concentrates appropriately with dehydration alone (>500–800), no further rise with DDAVP
— Copeptin = C-terminal fragment of pre-provasopressin, stable surrogate for ADH
— Baseline copeptin >21.4 pmol/L → diagnoses NDI without water deprivation
— Hypertonic saline-stimulated copeptin (target Na⁺ 150): >4.9 pmol/L excludes CDI; <4.9 confirms CDI. Distinguishes CDI from primary polydipsia with ~95% accuracy — superior to water deprivation
— MRI of pituitary and hypothalamus with gadolinium for CDI — look for absent posterior pituitary "bright spot" on T1, thickened pituitary stalk (>3 mm), masses, infiltrative disease
— Renal ultrasound in NDI to exclude obstruction; consider genetic testing in early-onset familial NDI
— Partial CDI and partial NDI overlap on water deprivation — copeptin helps
— Long-standing primary polydipsia can blunt medullary concentration gradient, falsely mimicking partial NDI
Board pearl: Loss of the posterior pituitary bright spot on T1 MRI supports central DI but is not specific (seen in 10–20% of normals and in elderly).
Step 3 management: Order hypertonic saline-stimulated copeptin where available — it has replaced water deprivation in many academic centers because of safety and accuracy. The vignette may describe it as "stimulated copeptin testing."
— Is this central or nephrogenic?
— Is the patient hypernatremic and symptomatic (acute)?
— Does the patient have intact thirst and water access (chronic)?
— Calculate free water deficit: 0.6 × weight(kg) × [(Na⁺/140) − 1]
— Correct slowly: lower Na⁺ by ≤10–12 mEq/L per 24 hr (≤0.5 mEq/L/hr) to avoid cerebral edema
— Use D5W or oral free water preferentially; ½ NS if hemodynamically unstable
— Add ongoing urinary losses to deficit calculation
— Give desmopressin (DDAVP) 1–2 µg IV/SC q8–12h or 10–20 µg intranasal
— Match urine output mL-for-mL with hypotonic fluid until DDAVP takes effect
— Beware the triphasic response — pause DDAVP if Na⁺ drops, urine concentrates spontaneously
— Outpatient DDAVP oral (0.1–0.4 mg q8–12h), sublingual, or intranasal
— Patients drink to thirst; avoid scheduled fluid intake
— Remove offending agent (stop lithium if safe, correct Ca²⁺/K⁺)
— Low-salt, low-protein diet
— Thiazide diuretic (HCTZ 25 mg/day) + amiloride (especially with lithium)
— NSAID (indomethacin) as adjunct in refractory pediatric cases
CCS pearl: When managing acute hypernatremic DI on CCS, advance the clock in short increments (1–2 hours) with serial Na⁺ checks — overcorrection is the #1 testable error and can cause cerebral edema and seizures.
Board pearl: Lower Na⁺ by no more than 10 mEq/L in 24 hours, even when severe; chronic hypernatremia tolerates slow correction better than fast.
— Routes: oral tablet (0.1–0.4 mg q8–12h), sublingual melt (60–240 µg), intranasal spray (10–40 µg/day in divided doses), IV/SC (1–4 µg q12–24h)
— Half-life 6–14 hr; titrate to allow brief daily "escape" of dilute urine to prevent water intoxication
— No vasoconstrictive effect (unlike native vasopressin) → safe in CAD
— Serum Na⁺ weekly during titration, then every 6–12 months
— Watch for hyponatremia — the major adverse effect; risk increased by NSAIDs, SSRIs, thiazides, excess fluid intake
— Educate: skip a dose if not thirsty or if breakthrough urination has not occurred
— Hydrochlorothiazide 12.5–25 mg daily — induces mild volume contraction, enhances proximal Na⁺/water reabsorption, paradoxically reduces urine output by 30–50%
— Amiloride 5–10 mg daily — blocks lithium uptake via ENaC, preferred adjunct in lithium-induced NDI; also K⁺-sparing (offsets thiazide hypokalemia)
— Indomethacin 1–2 mg/kg/day — reduces GFR and enhances ADH responsiveness; reserved for severe/pediatric cases due to GI and renal toxicity
— Chlorpropamide — historic; enhances ADH effect on collecting duct in partial CDI; rarely used (hypoglycemia)
— Carbamazepine — minor adjunct in partial CDI
— DDAVP + SSRI, NSAID, thiazide → increased hyponatremia risk
— Lithium + ACEi/ARB/NSAID → lithium toxicity precipitating worse NDI
Step 3 management: For a lithium-treated bipolar patient with NDI, do not abruptly stop lithium without psychiatry input — instead add amiloride first, which preserves mood stabilization while blocking renal lithium uptake.
Board pearl: A patient on DDAVP who develops headache, nausea, and confusion → check Na⁺ for iatrogenic hyponatremia, hold DDAVP, restrict fluids.
— Transsphenoidal resection of pituitary adenoma, craniopharyngioma, Rathke cleft cyst — may cause or relieve DI
— Post-op DI occurs in 20–30%; permanent in 2–10%
— Triphasic response (classic, ~3–5% of cases):
— Phase 1 (days 0–5): DI from axonal shock
— Phase 2 (days 5–10): SIADH from release of stored ADH from degenerating neurons
— Phase 3 (after day 10): permanent DI if >80–90% of magnocellular neurons destroyed
— Management: hold DDAVP between phases, allow demand dosing
— Sarcoidosis, Langerhans cell histiocytosis, IgG4 disease, lymphocytic hypophysitis — biopsy or empiric immunosuppression (glucocorticoids)
— Germinoma, metastases — radiation/chemotherapy
— Relieve urinary tract obstruction (post-obstructive diuresis self-resolves but may reveal underlying tubular damage)
— Renal biopsy rarely needed
— Investigational: chaperone therapy, statins (clinically experimental for AQP2 trafficking)
— Consider lithium discontinuation with psychiatry; if essential, dose-reduce + amiloride
— Rarely, hemodialysis for acute lithium toxicity with severe DI
— No procedure cures thirst defect — requires fixed daily water prescription based on weight and urine output, scheduled DDAVP, frequent Na⁺ checks
— High morbidity from recurrent hypernatremia
CCS pearl: After transsphenoidal surgery, discharge orders must include: home Na⁺ check at 7 days, weight monitoring, sick-day rules for DDAVP, and outpatient endocrinology follow-up at 2 weeks — readmission for hyponatremia in the SIADH phase is a tested patient-safety event.
Board pearl: Stalk effect: pituitary mass compressing the stalk → mild hyperprolactinemia + CDI + anterior hypopituitarism — order full pituitary panel.
— Diminished thirst response (osmoreceptor blunting with aging) → higher risk of hypernatremic dehydration even with mild DI
— Polypharmacy: lithium, demeclocycline, foscarnet, tolvaptan, SGLT2 inhibitors can mimic or exacerbate polyuria
— Cognitive impairment → cannot reliably express thirst; bedside Na⁺ surveillance mandatory in nursing homes
— Start DDAVP at the lowest dose (e.g., oral 0.05 mg qHS) and titrate; oral preferred over intranasal in patients with rhinitis or unreliable absorption
— Falls risk from nocturia: a single bedtime DDAVP dose can help quality of life
— Both DI types may coexist with CKD; concentrating ability declines naturally with low GFR
— In lithium-induced NDI, monitor for chronic interstitial nephritis with progressive CKD — periodic renal ultrasound, urine microalbumin
— Thiazides lose efficacy at eGFR <30 — switch to loop diuretic + amiloride combinations or consult nephrology
— Indomethacin contraindicated in advanced CKD
— DDAVP dose adjustment usually unnecessary but watch for fluid retention
— No specific dose adjustment for DDAVP
— Caution with NSAIDs in cirrhosis (variceal bleeding, hepatorenal)
— Cirrhotic patients may have coexisting dilutional hyponatremia — avoid mistaking for DDAVP overdose
— Confirm patient or caregiver can read Na⁺ alerts, follow sick-day rules, and access free water
— Coordinate with home health when needed
Step 3 management: In any elderly DI patient hospitalized for an unrelated illness (pneumonia, UTI), hold one DDAVP dose on admission if Na⁺ is <135, and have the patient demonstrate water-deficit signs before resuming — most inpatient overcorrections are iatrogenic from continued home-dose DDAVP plus IV fluids.
Board pearl: Lithium-induced NDI may be partially irreversible after >15 years of use; aim for prevention via lowest effective lithium level (0.6–0.8 mEq/L) and avoid dehydration triggers.
— Caused by placental vasopressinase that degrades endogenous ADH; typically presents in 2nd–3rd trimester
— May unmask subclinical CDI or partial NDI
— Resolves 4–6 weeks postpartum
— DDAVP is treatment of choice — resistant to vasopressinase, FDA pregnancy category B, safe in breastfeeding
— Differential: preeclampsia/HELLP with AKI, acute fatty liver — both can cause acute kidney dysfunction with polyuria
— DDAVP dose may need to increase 50–100% in 2nd–3rd trimester
— Continue postpartum, taper after vasopressinase clears
— Infants: failure to thrive, recurrent fevers, vomiting, hypernatremic dehydration, irritability — easily missed
— Hereditary NDI (X-linked AVPR2, AR/AD AQP2): boys with first-year polyuria, normal copeptin
— Hereditary CDI (AVP gene, autosomal dominant): onset 1–6 years
— Acquired CDI in kids: craniopharyngioma, germinoma, Langerhans cell histiocytosis (eczematous rash, lytic skull lesions)
— DDAVP for CDI — start low (oral 0.05 mg qHS), titrate carefully; nasal route unreliable in infants
— NDI in kids: low-solute diet (low Na⁺, low protein), thiazide + amiloride ± indomethacin, frequent small feeds
— Growth monitoring, neurodevelopmental tracking
Board pearl: A child with polyuria + bone pain or skull lesions + seborrheic rash → Langerhans cell histiocytosis with CDI. Order skeletal survey and MRI pituitary; biopsy a lesion for diagnosis.
Key distinction: Gestational DI is transient and ADH-related (placental enzyme), not a primary hypothalamic or renal defect — but the treatment is identical (DDAVP), only the duration differs.
Step 3 management: In a pregnant patient with new polyuria and hypernatremia, simultaneously evaluate for preeclampsia and acute fatty liver of pregnancy — both can coexist and dramatically alter management priorities.
— Acute Na⁺ >155 with neurologic symptoms (seizures, coma) — emergency
— Cellular dehydration of brain → demyelination, intracranial hemorrhage from bridging vein tears
— Mortality up to 40–70% in severe acute hypernatremia in elderly
— From excess DDAVP or excess hypotonic fluid replacement
— Causes cerebral edema, seizures, herniation
— Especially dangerous when correcting chronic hypernatremia too fast (>12 mEq/L/24 hr)
— Most common chronic complication
— Headache, nausea, lethargy, seizures
— Triggered by excess water intake, NSAIDs, SSRIs, thiazides
— Chronic high-volume urine flow → megacystis, hydroureter, hydronephrosis
— Long-term NDI patients may develop CKD from chronic distension
— Chronic tubulointerstitial nephritis → progressive CKD
— Microcysts on imaging
— Continued lithium worsens NDI even after discontinuation in severe cases
— Pediatric NDI with recurrent hypernatremic dehydration → intellectual disability if untreated
— Recurrent hypernatremia, venous thrombosis from hyperviscosity, rhabdomyolysis
— High mortality without strict water prescription
— CDI often accompanied by anterior pituitary deficits — secondary hypothyroidism, adrenal insufficiency, hypogonadism
— Missed cortisol deficiency can be fatal during illness
CCS pearl: When correcting hypernatremia, recheck Na⁺ every 2–4 hours and adjust the rate. The CCS clock rewards proactive lab ordering; falling behind on labs is the most common test-day error.
Board pearl: Sudden hyponatremia in a stable DDAVP patient → look for new SSRI prescription, diuretic, or excess water intake before adjusting DDAVP dose.
— Severe hypernatremia (Na⁺ >160) with altered mental status, seizures, or hemodynamic instability
— Adipsic DI with acute decompensation
— Postoperative pituitary patient with massive polyuria + hypovolemia
— Severe lithium toxicity requiring dialysis
— Coexistent adrenal crisis (cortisol deficiency + DI)
— All confirmed CDI (long-term DDAVP titration, MRI interpretation, pituitary panel)
— NDI for evaluation of secondary causes and chronic management
— Adipsic DI — mandatory comanagement
— Pregnant patients with DI
— Lithium-induced NDI with declining eGFR
— Refractory NDI requiring multi-drug regimen
— Renal biopsy considerations
— Newly identified pituitary or hypothalamic mass with CDI
— Post-op CSF leak with polyuria (mimics DI but isotonic)
— Na⁺ <150 with intact thirst, oral intake possible → outpatient with rapid endo follow-up
— Na⁺ 150–160, mild symptoms → general medical floor with q4–6h Na⁺
— Na⁺ >160, AMS, infants, adipsic patients → ICU
— Need for hypertonic saline copeptin testing
— Pituitary surgery evaluation
— Pediatric hereditary NDI with refractory disease
— Stable Na⁺ on two consecutive values
— Demonstrated DDAVP technique
— Written sick-day rules
— Follow-up arranged in 1–2 weeks
Step 3 management: A post-pituitary surgery patient ready for floor discharge needs 48 hours of stable Na⁺, a teach-back on DDAVP dosing, a wallet card listing medications, and an endocrine appointment in 1 week — readmission within 30 days for hyponatremia is a tracked quality metric.
Board pearl: Suspect coexisting adrenal insufficiency in any hypotensive DI patient — give empiric stress-dose hydrocortisone 100 mg IV before further workup.
— CDI causes:
— Idiopathic (30%, often autoimmune lymphocytic infundibuloneurohypophysitis)
— Post-neurosurgical / post-traumatic
— Tumor: craniopharyngioma, germinoma, metastasis (breast, lung), pituitary macroadenoma extending superiorly
— Infiltrative: sarcoidosis, Langerhans cell histiocytosis, IgG4 disease, granulomatosis with polyangiitis
— Infection: TB, syphilis, encephalitis
— Vascular: Sheehan syndrome (postpartum pituitary necrosis), pituitary apoplexy
— Genetic: AVP gene mutations (autosomal dominant familial CDI), Wolfram syndrome (DIDMOAD)
— NDI causes:
— Drugs: lithium (most common acquired), demeclocycline, foscarnet, amphotericin B, cidofovir, tolvaptan, ofloxacin
— Electrolyte: chronic hypercalcemia, hypokalemia
— Obstructive uropathy and post-obstructive diuresis
— Sickle cell nephropathy
— Amyloidosis, Sjögren syndrome
— Genetic: X-linked AVPR2 mutation (90% of hereditary NDI, affects boys); autosomal AQP2 mutations
— Primary polydipsia:
— Psychogenic (schizophrenia, anxiety)
— Dipsogenic (hypothalamic thirst center lesion)
— Iatrogenic (high water intake advice)
— Gestational DI: placental vasopressinase
— Diabetes Insipidus + Diabetes Mellitus + Optic Atrophy + Deafness
— Autosomal recessive WFS1 mutation; childhood onset
— Comprehensive endocrine and ophthalmologic care
Key distinction: A patient with polyuria and Posm <280 with low Uosm is drinking too much (primary polydipsia); a patient with Posm >295 with low Uosm has true DI.
Board pearl: New CDI + diabetes mellitus + sensorineural hearing loss in a young patient → think Wolfram syndrome; genetic counseling indicated.
Step 3 management: Order an MRI pituitary in every newly diagnosed CDI — a tumor is identified in up to 50% of "idiopathic" cases on long-term follow-up, so repeat MRI in 1–3 years if initially negative.
— Uncontrolled diabetes mellitus (glucosuria) — most common
— Mannitol, IV contrast, high-protein tube feeds (urea diuresis)
— Post-obstructive diuresis
— SGLT2 inhibitors (canagliflozin, empagliflozin, dapagliflozin)
— Urine osmolality is >300 in solute diuresis vs <300 in water diuresis
— Loop and thiazide diuretics, especially in heart failure or cirrhosis
— Acetazolamide
— Often nocturia predominates; Uosm modest 200–400
— Can cause NDI but also independent polyuria from tubular dysfunction
— Hyponatremic + hypovolemic + high urine Na⁺ — distinguish from SIADH (euvolemic)
— Not DI — it's salt loss, not water loss
— Acute ADH suppression — usually identifiable by history
— Anticholinergic drugs, Sjögren syndrome — drinking habit not true thirst
— Athletes overhydrating, "hydration culture" misinformation
Key distinction: SIADH and DI are opposites: SIADH = inappropriate ADH → concentrated urine + hyponatremia; DI = absent/ineffective ADH → dilute urine + hypernatremia. Both can occur sequentially in the triphasic response post-pituitary surgery.
Board pearl: Hyponatremia in a hospitalized patient on tolvaptan being held → consider DI from tolvaptan effect persisting; conversely, abrupt tolvaptan stop in SIADH can rebound.
Step 3 management: Always recheck a finger-stick glucose and review the medication list before ordering a water deprivation test — uncontrolled diabetes and diuretics explain most "polyuria" referrals in primary care.
— Lifelong DDAVP, titrated to allow brief daily breakthrough urination (prevents water intoxication)
— Annual TSH/T4, AM cortisol, IGF-1, prolactin, LH/FSH/testosterone or estradiol — anterior pituitary deficits can emerge years after DI onset
— Annual or biennial pituitary MRI for at least 3 years in "idiopathic" cases; longer if etiology remains unclear
— Bone density (DXA) every 2 years if hypogonadism or steroid replacement
— If lithium-induced: shared decision-making with psychiatry — alternatives (valproate, lamotrigine, quetiapine) vs continuing lithium with amiloride
— Renal function (eGFR, urine microalbumin) every 6–12 months
— Low-salt, low-protein diet counseling
— Monitor K⁺, glucose, uric acid on thiazide + amiloride
— Bladder ultrasound periodically in long-standing high-volume cases
— DDAVP with written instructions (dose, route, "skip a dose if not urinating freely")
— Thiazide ± amiloride for NDI
— Replacement hormones if hypopituitarism (levothyroxine, hydrocortisone, testosterone/estrogen, GH if indicated)
— Stress-dose steroid card if on glucocorticoid replacement
— Sick-day rules: GI illness with vomiting → call physician, may need IV fluids
— Avoid OTC NSAIDs without consulting prescriber (hyponatremia risk on DDAVP; AKI risk on NDI regimen)
— Medical alert bracelet
— Free water access at all times; never restrict water in DI patients
Step 3 management: Every DI patient should leave the hospital with a written sick-day action plan — readmission for hypernatremia after gastroenteritis is a preventable safety event tracked under transitions-of-care quality metrics.
Board pearl: Hypopituitarism with cortisol deficiency masks DI (cortisol is required for free water excretion). When cortisol is replaced, latent DI can suddenly manifest — anticipate this in Sheehan and apoplexy patients.
— Week 1–2 post-diagnosis or post-discharge: clinic visit, serum Na⁺
— Months 1, 3, 6: Na⁺, weight, symptom check, DDAVP titration
— Stable patients: every 6–12 months with annual labs (CMP, osmolality if needed, pituitary panel for CDI, eGFR for NDI)
— More frequent during dose changes, intercurrent illness, pregnancy
— Serum sodium (target 135–145)
— 24-hr urine volume (target <3 L/day on therapy if feasible)
— Body weight (proxy for fluid balance)
— Symptoms: nocturia frequency, thirst, headache, lethargy
— Quality of life: sleep, work performance, activity tolerance
— Thirst-driven drinking is safest; avoid both forced fluid restriction and forced fluid intake
— Recognize hyponatremia symptoms: headache, nausea, confusion, muscle cramps
— Recognize hypernatremia symptoms: intense thirst, dry mouth, weakness, confusion
— Travel: pack extra DDAVP, prescription copy, medical alert
— Heat/exercise: increase water intake to thirst, don't increase DDAVP
— Children: school nurse coordination, free bathroom access, free water access during class
— Adipsic DI patients need structured fluid regimens with caregiver involvement
— Cognitive impaired or institutionalized patients require nursing-driven I/O records
— Mental health support for adolescents and adults with chronic disease burden
— Severe nocturia + daytime sleepiness can affect commercial driving; document
— Patients on lithium NDI: monitor for cognitive side effects
CCS pearl: On every DI follow-up encounter, order serum Na⁺ and review weight trend — these two parameters detect both undertreatment and overtreatment before symptoms manifest.
Board pearl: A stable DDAVP patient who suddenly develops hyponatremia → ask about new SSRI, NSAID, thiazide, or a recent change in fluid intake habits before adjusting DDAVP.
— Patient must understand risks of dehydration, hypernatremia, and rare seizures
— Test must be directly supervised with stop criteria documented
— In psychiatric patients with primary polydipsia, capacity assessment is crucial — many lack insight; consider involving a surrogate decision-maker for sustained fluid management
— Forced fluid restriction in psychiatric inpatients with primary polydipsia is an ethical gray zone — least-restrictive interventions first (behavioral plan, scheduled offerings)
— Document attempts at voluntary cooperation before restraints
— Suspected child neglect when an infant with NDI has recurrent hypernatremic dehydration episodes — assess caregiver education vs willful neglect; involve social work
— Sentinel events: postoperative hypernatremia >160 or hyponatremia <120 from DDAVP overdose are reportable in many hospital systems
— DDAVP is on most hospital "high-alert medication" lists
— Common error: home DDAVP continued on admission while patient receives liberal IV fluids → severe hyponatremia
— Fix: medication reconciliation must explicitly flag DDAVP with a fluid management plan
— Discharge: explicit teach-back about resuming home dose, weight log, written sick-day rules
— Shared decision-making with psychiatry on continuing lithium despite NDI/CKD — balance mood stability vs renal outcomes
— Document discussion of alternatives
— Severe nocturia and daytime sleepiness — assess and counsel; do not stigmatize
— Adolescents with congenital NDI should be educated to take ownership of monitoring before transitioning to adult care — formal transition clinic preferred
Step 3 management: On admission medication reconciliation for any patient on DDAVP, write a standing order to hold DDAVP if Na⁺ <135 and to notify physician — this single safety measure prevents most iatrogenic hyponatremic seizures during hospitalization.
Board pearl: A "never event" in DI care is severe hyponatremic seizure from continued DDAVP + IVF in a hospitalized patient — recognize the system error, not just the medical one.
Board pearl: Memorize the DDAVP escape window concept — letting urine briefly dilute once a day prevents chronic hyponatremia in CDI patients.
Key distinction: SIADH = wet brain/dry urine; DI = dry brain/wet urine.
Step 3 management: When the stem mentions "post-neurosurgical patient with urine output >250 mL/hr × 2 hours plus rising Na⁺" — the answer is start DDAVP and match urine output with hypotonic fluid.
Board pearl: If the stem gives Na⁺ and Posm but not Uosm, suspect the question is testing your ability to order the right next test (Uosm + urine specific gravity).
Diabetes insipidus is hypotonic polyuria from either deficient ADH secretion (central DI, treated with desmopressin) or renal resistance to ADH (nephrogenic DI, treated by removing the offending agent — usually lithium, hypercalcemia, or hypokalemia — and adding thiazide ± amiloride), distinguished from primary polydipsia by serum/urine osmolality and response to DDAVP, with management always anchored by free water balance, slow sodium correction (≤10–12 mEq/L per 24 hours), and recognition of the postoperative triphasic response.
Board pearl: The most testable single fact on Step 3 DI: distinguishing CDI from NDI hinges on the response to desmopressin, and the most testable safety fact is slow correction of sodium to prevent cerebral edema.